The animals were administered a fixed daily dose of 0.2 mg/kg of semaglutide in 0.5 mL (Ozempic, Novo Nordisk, Bagsvrd, Denmark) subcutaneously on the back
About this article Cite this article Dooley, T.P., Kindt, K.E
These long-acting incretin receptor agonists have revolutionized the landscape of obesity and T2D research and are now being explored for other metabolic disorders, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) [3]
However, it contains higher dosage amounts of semaglutide and is FDA-approved for weight loss in people with obesity and overweight
Biosynthesis and Regulation of g-Glutamyl Transpeptidase 9
Hypertension 52 , 11201126 (2008)